Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb – Research Grade

Description of Eurestobart Biosimilar - Anti-Ecto-ATP diphosphohydrolase 1 mAb - Research Grade

Introduction to Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb

Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb is a research-grade antibody that has been developed as a biosimilar to the original Eurestobart antibody. This antibody specifically targets the enzyme Ecto-ATP diphosphohydrolase 1 (E-NTPDase1), which is involved in the regulation of extracellular adenosine triphosphate (ATP) levels. In this article, we will explore the structure, activity, and potential applications of this biosimilar antibody.

Structure of Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb

Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains are responsible for the antibody’s binding specificity, while the light chains aid in stabilizing the structure.

The variable regions of the heavy and light chains contain antigen-binding sites, which are responsible for recognizing and binding to the target protein, E-NTPDase1. The constant regions of the antibody are responsible for mediating effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb

Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb binds specifically to E-NTPDase1, inhibiting its activity and preventing the breakdown of extracellular ATP. This results in an accumulation of ATP in the extracellular space, which can then be converted to adenosine by other enzymes. Adenosine is an important signaling molecule that regulates various physiological processes, including inflammation and immune responses.

In addition to its inhibitory activity, Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb also has effector functions that can contribute to its therapeutic potential. The antibody can induce ADCC and CDC, leading to the destruction of cells expressing E-NTPDase1. This can be beneficial in conditions where E-NTPDase1 is overexpressed, such as cancer or autoimmune diseases.

Title: Applications of Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb

Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb has potential applications in both research and therapeutic settings. In research, this biosimilar antibody can be used to study the role of E-NTPDase1 in various physiological processes, such as inflammation and immune responses. It can also be used to investigate the potential of targeting E-NTPDase1 as a therapeutic strategy for various diseases.

In terms of therapeutics, Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb has shown promise in preclinical studies for the treatment of conditions such as cancer and autoimmune diseases. By targeting E-NTPDase1, this antibody can potentially modulate immune responses and inhibit tumor growth. It may also have potential as an adjunct therapy in combination with other treatments.

Conclusion

In summary, Eurestobart Biosimilar – Anti-Ecto-ATP diphosphohydrolase 1 mAb is a research-grade antibody that specifically targets E-NTPDase1. It has a unique structure, with both inhibitory and effector functions, making it a promising candidate for both research and therapeutic applications